NASDAQ:PATH - NuPathe Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous Close$5.85
Today's Range$5.20 - $5.87
52-Week RangeN/A
Volume9,920 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.

Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for PATH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:PATH
CUSIPN/A
Phone+1-610-2320800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
OptionableNot Optionable

NuPathe (NASDAQ:PATH) Frequently Asked Questions

What is NuPathe's stock symbol?

NuPathe trades on the NASDAQ under the ticker symbol "PATH."

Has NuPathe been receiving favorable news coverage?

News stories about PATH stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. NuPathe earned a news sentiment score of 1.6 on InfoTrie's scale. They also gave news articles about the healthcare company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.

How do I buy shares of NuPathe?

Shares of PATH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuPathe's official website?

The official website for NuPathe is http://www.nupathe.com.

How can I contact NuPathe?

NuPathe's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at +1-610-2320800.


MarketBeat Community Rating for NuPathe (NASDAQ PATH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  106
MarketBeat's community ratings are surveys of what our community members think about NuPathe and other stocks. Vote "Outperform" if you believe PATH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PATH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel